Plasma β-amyloid in Alzheimer's disease and vascular disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer’s disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Correlations between plasma and CSF Aβ and between plasma Aβ and [18F]flutemetamol SUVR. (A–C) Plasma (Simoa immunoassay) and CSF (Euroimmun immunoassay) Aβ42 and Aβ40 were measured in a cohort of 719 individuals (174 SCI, 214 MCI, 57 AD patients and 274 controls). (D–F) Neuocortical amyloid deposition was measured using [18F]flutemetamol PET in a cohort of 340 individuals (103 SCI, 112 MCI patients and 125 controls). Correlation coefficients (r) and p-values are from Pearson’s correlation analysis. AD, Alzheimer’s disease; CSF, cerebrospinal fluid; SCD, subjective cognitive decline; MCI, mild cognitive impairment; PET, positron emission tomography; SUVR, standardized uptake value ratio.](https://figures.cochat.ai/paper-figures/71bfab0f50314c6182d3ebedc2d5d0c6/plasma-amyloid-in-alzheimer-s-disease-and-vascular-disease-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“more recent studies have demonstrated that it correlates with brain Aβ and can differentiate patients with AD from healthy control participants.12,13”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many candidate blood biomarkers have failed in replication studies,7,8 but somewhat promising results have been seen for plasma tau, neurofilament light chain (NFL), and combinations of Aβ42 and Aβ40.9,10,11,12,13,14,15,16,17”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a 65-year-old woman with only amyloid biomarkers but who is cognitively normal and has no neurodegeneration has a 10-year Alzheimer's disease risk of 2·5% and a man 2·3%, but the risk is higher with accompanying neurodegeneration (table 2 ).185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A model of lifetime risks of people who are amyloid positive without any other biomarkers finds it to be 8·4% for a 90-year-old woman who is cognitively normal at baseline, 23·5% for a 75-year-old woman and 29·3% for a 65-year-old woman.185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredIn the citing paper
“Although previous studies have found associations between CSF and PET Aβ and plasma Aβ using different immunoassays,7,12,13,14,44,45 the present Elecsys assays produced among the best accuracies and they are the first fully automated assays to have these greater accuracies.”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationRissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationA New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L. O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Ader, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,797
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zlokovic, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 860
Research works printed but not linked: 1
- Janelidze, S. et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology (In press).
Cited by
Items 401–500 of 628
Dominguez, J. C., Yu, J. R. T., Guzman, M. F. D., Ampil, E. R., Guevarra, A. C., Joson, M. L. C., Reandelar, M., Martinez, M., Ligsay, A. D., Ocampo, F. F., et al. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9960832 · Cited by 14
Tiwari, P., Gupta, A., Kaushik, M., Yadav, A., Anjali, A., Dwivedi, R., Mudgal, P., Kumar, Y., Tripathi, M., & Dada, R. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf410 · Cited by 11
LRP1 at the crossroads of Aβ clearance and therapeutic targeting in Alzheimer’s disease
Deng, Y., Yin, H., Lu, Z., Lan, H., Liu, W., Zuo, C., Pan, N., Tian, X., & Gong, Q. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1669405 · Cited by 16
Cognitive Deficits in Type-1 Diabetes: Aspects of Glucose, Cerebrovascular and Amyloid Involvement
Pickering, J., Wong, R. H. X., Al‐Salami, H., Lam, V., & Takechi, R. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03100-1 · Cited by 12
Predicting neurodegeneration from sleep related biofluid changes
Yang, Y., Kim, W. S., Michaelian, J. C., Lewis, S. J. G., Phillips, C. L., D'Rozario, A. L., Chatterjee, P., Martins, R. N., Grunstein, R. R., Halliday, G. M., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106369 · Cited by 11
Takeuchi, L. E., Kalia, L. V., & Simmons, C. A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106864 · Cited by 13
Blutbasierte Biomarker zur Optimierung der Früh- und Differentialdiagnostik der Alzheimer-Demenz
Hansen, N., Rauter, C. M., & Wiltfang, J. (2022) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1839-6237 · Cited by 16
Piccarducci, R., Caselli, M. C., Zappelli, E., Ulivi, L., Daniele, S., Siciliano, G., Ceravolo, R., Mancuso, M., Baldacci, F., & Martini, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220216 · Cited by 12
Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer’s disease
Sheu, J., Yang, L., Sanotra, M. R., Wang, S., Lu, H., Kam, R. S. Y., Hsu, I.-U. Y., Kao, S., Lee, C., Shieh, J. C.-C., et al. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.11.011 · Cited by 11
Rossi, E., Tran, N. T., Hirtz, C., Lehmann, S., & Taverna, M. (2020) · Talanta · doi:10.1016/j.talanta.2020.121002 · Cited by 11
Connecting Mind-Body Therapy-Mediated Effects to Pathological Features of Alzheimer’s Disease
Hüttenrauch, M., López‐Noguerola, J. S., & Castro‐Obregón, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200743 · Cited by 12
Gao, H., Wang, J., Liu, J., Ye, S., Meng, X. W., Song, S., Wang, C., Yu, X., Zhu, L., Wang, H., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00613 · Cited by 10
Schraen‐Maschke, S., Duhamel, A., Vidal, J., Ramdane, N., Vaudran, L., Dussart, C., Buée, L., Sablonnière, B., Delaby, C., Allinquant, B., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106459 · Cited by 9
The Inflammasome Adaptor Protein ASC in Plasma as a Biomarker of Early Cognitive Changes
Cyr, B. S., Curiel, R. E., Loewenstein, D., Vontell, R., Dietrich, W. D., Keane, R. W., & Vaccari, J. P. D. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147758 · Cited by 9
Suárez‐Calvet, M., Ruiz, C. A., Alcolea, D. A., Mendióroz, M., Balasa, M., Morenas‐Rodríguez, E., Puig‐Pijoan, A., Sánchez‐Juan, P., Villarejo‐Galende, A., & Sánchez‐Valle, R. (2024) · Neurología · doi:10.1016/j.nrl.2024.08.002 · Cited by 12
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
Bhalala, O. G., Watson, R., & Yassi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021231 · Cited by 11
Jankevičiūtė, S., Pšemeneckienė, G., Morkūnienė, R., Grušauskienė, E., Petrikonis, K., Rastenytė, D., & Borutaitė, V. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14389 · Cited by 8
Li, D., Mielke, M. M., Bell, W. R., Reilly, C., Zhang, L., Lin, F. V., & Yu, F. (2020) · Trials · doi:10.1186/s13063-019-3798-1 · Cited by 10
Wang, X., Zhao, M., Li, L., & Han, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.592024 · Cited by 10
Tin, A., Sullivan, K., Walker, K. A., Bressler, J., Talluri, R., Yu, B., Simino, J. M., Guðmundsdóttir, V., Emilsson, V., Jennings, L. L., et al. (2022) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2022.04.005 · Cited by 9
Faldu, K. G., & Shah, J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2104639 · Cited by 10
Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
Tsantzali, I., Foska, A., Sideri, E., Routsi, E., Tsomaka, E., Kitsos, D. K., Zompola, C., Bonakis, A., Giannopoulos, S., Voumvourakis, K. I., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10081879 · Cited by 9
Itri, S., del Giudice, D., Mugnano, M., Tkachenko, V., Uusitalo, S., Kokkonen, A., Päkkilä, I., Ottevaere, H., Nie, Y., Mazzon, E., et al. (2022) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2022.100536 · Cited by 9
Degradation of amyloid β-peptides catalyzed by nattokinase in vivo and in vitro
Ni, A., Li, H., Wang, R., Sun, R., & Zhang, Y. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.02.042 · Cited by 9
Serum amyloid beta 42 levels correlated with metabolic syndrome and its components
Li, K., Zhou, X., Liu, Y., Li, D., Li, Y., Zhang, T., Fu, C., Li, L., Hu, Y., & Jiang, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1278477 · Cited by 12
Biofluid biomarkers for Alzheimer’s disease
Wang, S., Xie, S., Zheng, Q., Zhang, Z., Wang, T., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380237 · Cited by 11
Suárez‐Calvet, M., Ruiz, C. A., Alcolea, D. A., Mendióroz, M., Balasa, M., Morenas‐Rodríguez, E., Puig‐Pijoan, A., Sánchez‐Juan, P., Villarejo‐Galende, A., & Sánchez‐Valle, R. (2025) · Neurología (English Edition) · doi:10.1016/j.nrleng.2025.07.004 · Cited by 16
Liu, H.-C., Chen, H.-H., Ho, C.-S., Chang, J.-F., Lin, C.-C., Chiu, M., Chen, T., Hu, C., Yan, S., Sun, Y., et al. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00280-1 · Cited by 8
Pomilio, A. B., Vitale, A. A., & Lazarowski, A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220413094918 · Cited by 9
Exposure to Low-Intensity Blast Increases Clearance of Brain Amyloid Beta
Abutarboush, R., Reed, E., Chen, Y., Gu, M., Watson, C., Kawoos, U., Statz, J. K., Tschiffely, A. E., Ciarlone, S. L., Garcia, G. S. P., et al. (2024) · Journal of Neurotrauma · doi:10.1089/neu.2023.0284 · Cited by 10
The possible impact of cervical stenosis on cephalad neuronal dysfunction
Khachatryan, T., & Robinson, J. S. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.06.008 · Cited by 8
Biomarcadores en la enfermedad de Alzheimer
Janeiro, M. H., Ardanaz, C. G., Sola-Sevilla, N., Dong, J., Cortés-Erice, M., Solas, M., Puerta, E., & Ramírez, M. J. (2021) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2020-0109 · Cited by 33
Achard, V., Ceyzériat, K., Tournier, B. B., Frisoni, G. B., Garibotto, V., & Zilli, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734881 · Cited by 9
Bias-generating factors in biofluid amyloid-β measurements for Alzheimer’s disease diagnosis
Park, S., & Kim, Y. S. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00201-z · Cited by 9
Rajamani, G., Naqvi, S. N. H., & Sharma, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00211g · Cited by 10
CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer’s Dementia Spectrum
Behzad, M., Zirak, N., Madani, G. H., Baidoo, L., Rezaei, A., Karbasi, S., Sadeghi, M. R., Shafie, M., Mayeli, M., & Initiative, A. D. N. (2023) · International Journal of Alzheimer s Disease · doi:10.1155/2023/5336273 · Cited by 8
Early Alzheimer’s Disease Screening Approach Using Plasma Biomarkers
Álvarez‐Sánchez, L., Peña‐Bautista, C., Ferré‐González, L., Cubas-Núñez, L., Balaguer, Á., Casanova-Estruch, B., Baquero, M., & Cháfer‐Pericás, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814151 · Cited by 9
Abdullah, L. B., Zhou, Z., Hall, J., Petersen, M. E., Zhang, F., & O’Bryant, S. E. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251322966 · Cited by 7
Qu, W., Zhang, L., Liang, X., Yu, Z., Huang, H., Zhao, J., Guo, Y., Zhou, X., Xu, S., Luo, H., et al. (2023) · Biosensors · doi:10.3390/bios13010110 · Cited by 9
Recent Advances in Photoelectrochemical Sensing of Alzheimer’s Biomarkers
Kim, K. (2023) · BioChip Journal · doi:10.1007/s13206-023-00105-3 · Cited by 8
Small molecule biomarkers in Alzheimer’s disease
Kim, M. G., & Legido‐Quigley, C. (2018) · OCL · doi:10.1051/ocl/2018027 · Cited by 8
Dong, Y., Wang, Q., Yao, H., Xiao, Y., Wei, J., Xie, P., Hu, J., Chen, W., Tang, Y., Zhou, H., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28359 · Cited by 6
Singh, K., Cheung, B. M. Y., & Xu, A. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0219 · Cited by 8
Ahmed, T. F., Azmi, M. B., Imtiaz, F., Zaman, U., Ahmed, A., & Shahbaz, N. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.05.013 · Cited by 5
Clinical significance of plasma candidate biomarkers of Alzheimer’s Disease
Lewczuk, P., Łukaszewicz‐Zając, M., Kornhuber, J., & Mroczko, B. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.100675 · Cited by 11
Lohner, V., Perna, L., Schöttker, B., Perneczky, R., Brenner, H., & Mons, U. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112684 · Cited by 5
Monocytes exposed to plasma from patients with Alzheimer’s disease undergo metabolic reprogramming
Wolfe, H. E., Mela, V., Minogue, A. M., Miller, A., McGuigan, C., Williams, L., Lohan, D., LAWLOR, B. A., & Lynch, M. A. (2019) · Neuroscience Research · doi:10.1016/j.neures.2019.01.001 · Cited by 8
Zhang, S., Huang, S., An, X., Zeng, L., & Ai, J. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01510-1 · Cited by 6
van der Willik, K. D., Ghanbari, M., Fani, L., Compter, A., Ruiter, R., Stricker, B. H. C., Schagen, S. B., & Ikram, M. A. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0167 · Cited by 7
Prins, S., Zhuparris, A., Hart, E. P., Doll, R. J., & Groeneveld, G. J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00874-9 · Cited by 9
Zetterberg, H., Apostolova, L. G., & Snyder, P. J. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.10.001 · Cited by 7
Self-citationWei, M., Yu, X., Hu, S., Hu, W., Shi, R., Wang, M., Zhong, J., Zhang, Q., Zhang, Y., Li, C., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241309105 · Cited by 5
Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome
Sauer, M., Gomes, B. F., Shahrouki, P., Lantero‐Rodriguez, J., Montoliu‐Gaya, L., Camporesi, E., Belbin, O., Alcolea, D. A., Kumar, A., Sharma, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70241 · Cited by 8
Self-citationBarber, A., Chacon, R., Mann, F. D., Kritikos, M., Meliker, J. R., Kuan, P. F., Carr, M. A., Yang, X., Clouston, S., & Luft, B. J. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf135 · Cited by 5
Cerebral amyloid angiopathy-related cardiac injury: Focus on cardiac cell death
Xu, X., Xu, H., & Zhang, Z. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1156970 · Cited by 6
Tzekaki, E. E., Katsipis, G., Andreadou, E. G., Mouzakidis, C., Baldimtsi, E. N., Karathanasi, E. M., Hassandra, M., Galanis, E., Hatzigeorgiadis, A., Γούδας, Μ., et al. (2023) · Brain Disorders · doi:10.1016/j.dscb.2023.100090 · Cited by 5
Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting
Meyer, S. D., Blujdea, E. R., Schaeverbeke, J. M., Adamczuk, K., Vandenberghe, R. R., Poesen, K., & Teunissen, C. E. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70071 · Cited by 12
Cheng, Y., Tang, L., Yi, T., Xu, H., Yang, D., Zhou, Z., Gao, W., Ke, Z., Mao, C., Hu, Z., et al. (2025) · ACS Sensors · doi:10.1021/acssensors.5c03653 · Cited by 4
Advances in plasma biomarkers for the diagnosis of Alzheimer’s disease
Wu, H., Liu, L., & Zeng, L. (2026) · Brain Research · doi:10.1016/j.brainres.2025.150138 · Cited by 5
Guso, E., Lupoli, A., Olivieri, E., Bottoni, A., Gironi, M., Missarelli, D. M., Toosy, A., Rossi, E., & Furlan, R. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.02.047 · Cited by 4
Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics
Rippon, B., Palta, P., Tahmi, M., Sherwood, G., Soto, L., Cespedes, S., Mesen, Y., He, H., Laing, K. K., Moreno, H., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-210391 · Cited by 5
Self-citationParker, S., James, A. F., & Mastitskaya, S. (2025) · The Journal of Physiology · doi:10.1113/jp286599 · Cited by 4
Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers
Chen, T., Lin, K., Lin, S., Lee, Y., Lin, Y., Wang, C.-Y., Chen, J., & Wang, P. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.619388 · Cited by 4
Potential Protein Blood-based Biomarkers in Different Types of Dementia: A Therapeutic Overview
Manzine, P. R., Vatanabe, I. P., Grigoli, M. M., Pedroso, R. V., Monteiro, M. P. A. O., de Oliveira, D. D. S. M. S., Nascimento, C. M. C., Peron, R., Orlandi, F. D. S., & Cominetti, M. R. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220408124809 · Cited by 5
Smith, A. S., Gossman, K. R., Dykstra, B., Gao, F. P., & Moskovitz, J. (2022) · Antioxidants · doi:10.3390/antiox11040775 · Cited by 6
Innovative SALDI mass spectrometry analysis for Alzheimer's disease synthetic peptides detection
Cournut, A., Moustiez, P., Coffinier, Y., Enjalbal, C., & Bich, C. (2023) · Talanta · doi:10.1016/j.talanta.2023.125357 · Cited by 3
Solis‐Urra, P., Rodríguez‐Ayllón, M., Álvarez-Ortega, M., Molina‐Hidalgo, C., Molina‐García, P., Arroyo‐Avila, C., García‐Hermoso, A., Collins, A. M., Jain, S., Gispert, J. D., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230586 · Cited by 4
Sani, N. F. A., Hamzah, A. I. Z. A., Bakar, Z. H. A., Yusof, Y. A. M., Makpol, S., Ngah, W. Z. W., & Damanhuri, H. A. (2021) · Cells · doi:10.3390/cells10071611 · Cited by 6
Evolution of Detecting Early Onset of Alzheimer’s Disease: From Neuroimaging to Optical Immunoassays
Hsiao, W. W., Angela, S., Le, T., Ku, C., Hu, P., & Chiang, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221202 · Cited by 5
Elucidating the Functional Roles of Long Non-Coding RNAs in Alzheimer’s Disease
Huang, Z., Chen, Q., Mu, X., An, Z., & Xu, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179211 · Cited by 5
Delrieu, J. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch63 · Cited by 5
Arranz, J., Zhu, N., Rubio‐Guerra, S., Rodríguez‐Baz, Í., Carmona‐Iragui, M., Barroeta, I., Illán‐Gala, I., Santos‐Santos, M., Fortea, J., Lleó, A., et al. (2023) · medRxiv · doi:10.1101/2023.04.20.23288852 · Cited by 5
Johansson, C., Þórðardóttir, S., Laffita‐Mesa, J. M., Pannee, J., Rodriguez‐Vieitez, E., Zetterberg, H., Blennow, K., & Graff, C. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01574-w · Cited by 4
Self-citationDevelopment of a light-initiated chemiluminescence system for the detection of human plasma p-tau181
Yang, Y., & Wang, X. (2025) · The Analyst · doi:10.1039/d5an00590f · Cited by 3
Miglione, A., Kalligosfyri, P. M., Corbo, C., Calabria, D., Mirasoli, M., Frasconi, M., & Cinti, S. (2025) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2025.100687 · Cited by 5
Bae, H. J., Kim, S.-I., Kim, S.-Y., Cho, Y. E., Sung, S., Lim, S., Cho, K., Park, S. J., & Lim, S. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1672153 · Cited by 3
Mhatre‐Winters, I., Eid, A., Blum, N., Han, Y., Sammoura, F. M., Wu, L., & Richardson, J. (2025) · NeuroToxicology · doi:10.1016/j.neuro.2025.103343 · Cited by 4
Brembati, V., Crescenti, D., Geviti, A., Rossini, E., Cazzaniga, F. A., Moda, F., Zanier, E. R., Guerrera, G., Battistini, L., Baiardi, S., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01897-2 · Cited by 6
Shin, H.-Y., Yim, T., Heo, H.-M., Jahng, G., Kwon, S., Cho, S., Park, S.-U., Jung, W., Moon, S., Ko, C., et al. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03805-9 · Cited by 3
Baek, S., Lee, J. C., Byun, B. H., Park, S. Y., Ha, J. H., Lee, K. C., Yang, S., Lee, J., Hong, S., Han, G., et al. (2025) · Experimental Neurobiology · doi:10.5607/en25008 · Cited by 4
Tzekaki, E. E., Katsipis, G., Chatzikostopoulos, A., Koutoupa, A., Lavrentiadou, S. N., Tsolaki, M., & Pantazaki, Α. A. (2025) · Biology · doi:10.3390/biology14050548 · Cited by 4
Influence of Cortisol on the Fibril Formation Kinetics of Aβ42 Peptide: A Multi-Technical Approach
Nucara, A., Ripanti, F., Sennato, S., Nisini, G., Santis, E. D., Sefat, M., Carbonaro, M., Mango, D., Minicozzi, V., & Carbone, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116007 · Cited by 4
Potential biomarkers of early diagnosis of Alzheimer’s disease
Bogolepova, A. N., Makhnovich, E. V., Коваленко, Е. А., & Osinovskaya, N. A. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20221220917 · Cited by 3
Xu, Z. ‐., Li, O., Liang, Y., Wu, Z., Xu, J., Wang, L., Li, L., & Sun, Y. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s418700 · Cited by 3
Yu, Y., Xia, X., Meng, X., Li, D., & Qin, Q. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230085 · Cited by 3
Rossi, S., Prodi, E., Morese, R., Paone, G., Ruberto, T., & Sacco, L. (2023) · Neurology International · doi:10.3390/neurolint15030058 · Cited by 3
Gary, C., Hérard, A., Hanss, Z., & Dhénain, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00035 · Cited by 3
Zhang, W., Li, M., Zhou, X., Huang, C., Wan, K., Li, C., Yin, J., Zhao, W., Zhang, C., Zhu, X., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.993767 · Cited by 4
McIntire, L. B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240126 · Cited by 2
Advances in Alzheimer's Disease Biomarkers
Li, K., Gao, Y., Liu, M., & Chen, Y. (2024) · Current Alzheimer Research · doi:10.2174/0115672050366767241223050957 · Cited by 3
Body Fluid Biomarkers of Neurological Injury in HIV-1-Associated Neurocognitive Disorder
Mei-juan, Y., Zhang, X., Zhang, D., Zhang, Y., Wang, J., Zhang, Y., Gu, C., Zhang, X., & Wei, L. (2025) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2024.0053 · Cited by 4
Alterations in CNS-derived blood biomarkers during 30 days simulated microgravity
Schmidt, S. V., Odainic, A., Aretz, B., Frings‐Meuthen, P., Hönemann, J., Bohmeier, M., Liemersdorf, C., Mulder, E. R., Moestl, S., Heusser, K., et al. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1600708 · Cited by 2
Chen, Y., Li, M., Li, J., Liang, P., Cheng, Z., Wang, N., Zhang, X., Wang, Y., Zhang, N., Che, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70710 · Cited by 4
Wang, Z., Xia, K., Huang, X., Dongsheng, F., & Yang, Q. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251403565 · Cited by 2
Amyloid‐beta (1–40) peptide is associated with systemic metabolic health
Sopova, K., Delialis, D., Aivalioti, E., Georgiopoulos, G. A., Athanasopoulos, S., Zervas, G., Konstantaki, C., Sachse, M., Sigl, M., Duerschmied, D., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70171 · Cited by 2
Sun, X., Xia, X., Liu, Y., Qi, X., & Xu, T. (2026) · Advanced Sustainable Systems · doi:10.1002/adsu.70442 · Cited by 4
Tatar, A.-S., Colniță, A., Brezeștean, I.-A., & Boca, S. (2026) · Biophysical Reviews · doi:10.1007/s12551-026-01428-9 · Cited by 3
Kanoria, S., Veitch, D. P., Miller, M. J., Aisen, P. S. S., Beckett, L. A., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Lee, E. B., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71353 · Cited by 3
Plasma metabolomics of presymptomatic PSEN1 ‐H163Y mutation carriers: a pilot study
Natarajan, K., Ullgren, A., Khoshnood, B., Johansson, C., Laffita‐Mesa, J. M., Pannee, J., Zetterberg, H., Blennow, K., & Graff, C. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51296 · Cited by 2
Self-citationXu, Q., Yang, J., Cheng, F., Ning, Z., Xi, C., & Sun, Z. (2023) · Brain Sciences · doi:10.3390/brainsci13121624 · Cited by 2
Metadata
- Authors
- Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- National Hospital for Neurology and Neurosurgery (GB)
- Quanterix (United States) (US)
- University of Gothenburg (SE)
- Corresponding author
- Janelidze, Shorena
- Hansson, Oskar
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-05-31
- Volume
- 6
- Issue
- 1
- Pages
- 26801-26801
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4886210
- OpenAlex
- W2414917913
- Cited by
- 626
- References
- 49
- Citations by year
- 2026: 53 · 2025: 59 · 2024: 75 · 2023: 77 · 2022: 80 · 2021: 75 · 2020: 73 · 2019: 59 · 2018: 45 · 2017: 22 · 2016: 6
- FWCI
- 39.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Australian Government
- Crafoordska Stiftelsen
- Lunds Universitet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- plasma amyloid-beta, amyloid-beta 42, Aβ40, Alzheimer's disease, vascular disease, amyloid biomarkers, cerebrospinal fluid, white matter lesions, cerebral microbleeds, hypertension, diabetes mellitus, ischemic heart disease, mild cognitive impairment, subjective cognitive decline, amyloid PET, amyloid metabolism
- MeSH terms
- Aged, Alzheimer Disease, Female, Humans, Male, Vascular Diseases, Cohort Studies, Biomarkers, Amyloid beta-Peptides, Neocortex, Positron-Emission Tomography, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.